KR101779443B1 - Kit for fluorescence-linked immunochromatographic assay to diagnose brucellosis - Google Patents

Abstract

The present invention relates to a fluorescent immunoassay kit for diagnosing brucellosis, comprising a substrate on which smooth LPS (smooth lipopolysaccharide) antigen derived from Brucella strain is bound and a condensate in which a protein A / G is conjugated to a comain dendrimer, To a method for diagnosing a disease. The fluorescence immunoassay kit for diagnosing brucellosis of the present invention comprises a substrate immobilized with a Smooth LPS antigen derived from a brucella strain and a condensate in which a protein A / G is conjugated to a comarine dendrimer. Even if a small amount of a sample is used, Can be effectively used for diagnosis of brucellosis.

Description

[0001] The present invention relates to a kit for fluorescence-linked immunoassay for diagnosing brucellosis,

The present invention relates to a fluorescent immunoassay kit for diagnosing brucellosis, and more particularly, to a kit for detecting inflammation of brucellosis, which comprises a substrate on which smooth LPS (smooth lipopolysaccharide) antigen derived from Brucella strain is bound, and a condensation product in which a comin dendrimer And a method for diagnosing brucellosis using the kit. 2. Description of the Related Art [0002] The present invention relates to a fluorescence immunoassay kit for diagnosing brucellosis.

Brucellosis is one of the most common communicable diseases (human, 4th-army, and livestock) and is known to cause serious public health and economic problems both domestically and globally. In recent years, the infectious diseases seen in Korea have been explosively increasing in human and livestock. Therefore, it is urgent to take measures against the public concern.

The brucellosis causing Brucella disease is Brucella There are known abortus , B. melitensis , B. canis , B. ovis and B. suis , all of which infect the human body and cause serious illness. In domestic, Brucella Abortus is known to occupy a high percentage. When the brucellosis is infected, it infects the human body and shows a mortality rate of less than 10%. It shows persistent fever, headache, loss of appetite and breakdown and progresses to serious diseases such as endocarditis, encephalitis and arthritis. Symptoms are known to cause sterilization due to placental salts, endometritis, etc. in females and sterility due to testicular torsion and malformed sperm in males without any special external symptoms. Since the brucellosis bacterium proliferates within the cell and causes onset, antibiotics treatment for several years is required for a short period of time in case of human infection and improvement of the treatment method is urgent due to aftereffects due to the use of a large amount of antibiotics However, even if it is judged to be cured, it is often recurred within a few years and continuous observation is required. However, when bovine brucellosis is developed, it is difficult to diagnose early because the brucella are continuously discharged to the outside while maintaining a long-term carrier as a carrier without any special symptoms. In addition, the intracellular phagocytosis mechanism and intracellular proliferation There are not many results of previous studies and it is difficult to eradicate the diseases. In addition, even when the brucellosis is infected in the body, the immunogenicity is low and immune cells are difficult to be formed.

In particular, when bovine brucellosis develops in cattle, the bacterium is present in a high concentration in each part of the body (especially liver, spleen, lymph node, blood, etc.) of cattle, and the meat, liver, spleen and stomach And it is urgently necessary to prepare national measures against the brucellosis. For this purpose, Brucella spp. Is detected to confirm the onset of brucellosis. However, since the sensitivity is low and the detection efficiency is very low, there is a demand for development of a new diagnosis method. have.

For example, Korean Patent No. 0260381 discloses a method for diagnosing brucellosis using latex beads in which the brucella abortus strain is sensitized and sensitized. In Korean Patent No. 1270662, a 26 kDa recombinant antigen protein of Brucella abortus And LPS. US Patent No. 8,691,237 discloses a method for diagnosing brucellosis using a composition containing a small brucellosis protein. However, even when these methods are used, a satisfactory level of diagnostic efficiency is obtained It is a fact that I can not.

Under these circumstances, the present inventors have made extensive efforts to develop a method for more effectively diagnosing Brucella disease. As a result, they have found that smooth LPS (lipopolysaccharide), an antigen derived from B. abortus 1119-3, A fluorescence immunoassay kit for the diagnosis of brucellosis, which comprises a substrate and a condensate in which a protein A / G (protein A / G) is bound to a co-marin dendrimer, is developed. In the case of using the fluorescence immunoassay kit, The present inventors completed the present invention by confirming that Brucella's disease can be diagnosed more effectively.

It is an object of the present invention to provide a fluorescent immunoassay kit for brucellosis diagnosis.

It is another object of the present invention to provide a method of using a kit, Thereby providing a method for diagnosing an infectious disease.

The inventors have focused on comarine dendrimers while carrying out various studies to develop a method for more effectively detecting brucellosis. Typically, a sandwich ELISA kit for detecting an antibody contained in a sample binds an antigen with a labeling substance such as a fluorescent substance. Since the intensity of fluorescence emitted from the fluorescent substance bound to the antigen is limited, the antibody Is low, it is difficult to measure the change of the fluorescence intensity compared to the basal value. As a result of various studies to develop a means for amplifying the fluorescence intensity, a coumarin dendrimer (coumarin-3-deoxycholic acid), which is a modification of Coumarin dye which is one of the green fluorescent substances excited by LED light sources, dendrimer of the present invention can effectively amplify the intensity of fluorescence when a condensed product of protein A / G (protein A / G) is used.

Actually, the inventors of the present invention prepared a fluorescent immunoassay kit for diagnosis of brucellosis, comprising a substrate on which smooth LPS (lipopolysaccharide), an antigen of Brucellosis, is bound and a condensate in which a protein A / G is conjugated to a comarine dendrimer, As a result of applying a blood sample of bovine cows with brucellosis, the protein A / G contained in the condensate was bound to a constant region of various antibodies contained in the blood sample, resulting in a co-marine dendrimer-protein A / G- Wherein the complex comprising the anti-LPS antibody in the complex binds to the LPS antigen immobilized on the substrate, and wherein the complex comprising the anti-LPS antibody is amplified by a co-marin dendrimer contained in the complex bound to the substrate By detecting fluorescence, it was confirmed that the antibody can be effectively detected even when a small amount of anti-LPS antibody is present in the blood sample. In addition, the sensitivity and specificity of Brucella 's disease kits were compared with other types of detection kits.

As one embodiment for achieving the above object, the present invention provides a fluorescent immunoassay kit for diagnosing brucellosis comprising a condensate in which a co-marin dendrimer is conjugated with a protein A / G (protein A / G).

The fluorescent immunoassay kit for diagnosing brucellosis is diagnosed by detecting the antibody produced in the body of an animal by the smooth LPS antigen derived from the brucella strain and infecting the brucella strain to diagnose the onset of brucellosis, In order to detect the antibody, the condensate contained in the kit is used.

The term " coumarin dendrimer "of the present invention means a fluorescent substance having a wavelength range of 460 nm to 645 nm including a dendrimer structure in the form of a branch. The co-marin dendrimer has an advantage that it can induce a fluorescence signal even with a low intensity light emitted from an LED light source, and has been applied to a multi-fluorescent agent, a biosensor, and a fluorescent immunoassay kit.

The term "protein A / G " of the present invention refers to a recombinant fusion protein having a molecular weight of about 50 kDa in which the IgG binding domain of protein A (protein A) and protein G (protein G) it means. The protein A / G comprises the Fc region binding domain of four IgGs derived from Protein A and the Fc region binding domain of two IgGs derived from Protein G. Specific amino acids of the protein A / G protein are known in the art (Sikkema, J.W.D. (1989) Amer. Biotech. Lab, 7, 42, etc.).

The term " protein A " of the present invention means a 42 kDa surface protein derived from the cell wall of Staphylococcus aureus and expressed from the spa gene, and includes human, mouse, rat, , Guinea pig, rabbit, chicken, etc. The specific amino acid sequence of the protein A protein or the gene sequence information encoding the protein A protein is known in the art (Graille M, et al., Proc Natl Acad Sci USA 97 (10): 5399-5404., Etc.).

The term " protein G " of the present invention refers to an immunoglobulin binding protein derived from Staphylococcus strains of C and G groups and having a size of 65 kDa or 58 kDa. The variable region of the immunoglobulin (Fab domain) (Fc region). Specific amino acid sequences of the protein A protein or gene sequence information encoding the same are known in the art (Sjobring U, et al., (1991), J Biol Chem 266 (1): 399-405).

The term " Brucella sp. &Quot; of the present invention means a bacterium belonging to the first genus of aerobic gram-negative bacteria causing brucellosis, and is developed into aerobic or micro-aerobic bacteria and infected with humans and various animals It can be the cause of brucellosis.

The term "brucellosis " of the present invention means an infectious disease caused by an infection of various brucellosis, and when infected to a human body, it exhibits a mortality rate of less than 10% and has persistent fever, headache, anorexia, , And progress to serious diseases such as endocarditis, encephalomyelitis, and arthritis. Symptoms seen in infected animals include abortions due to placental salts in females, endometritis in females and testicular malformations in males and infertility due to malformed sperm. ≪ / RTI >

In the present invention, the Brucella disease can be interpreted as meaning bovine brucellosis, a forborn infectious disease caused by bovine brucella abortus in cattle, which is specifically produced in brucellosis An antibody against a smooth LPS antigen can be detected in a bovine sample and its infection can be diagnosed.

The term "smooth LPS (lipopolysaccharide)" of the present invention means a lipopolysaccharide composed of a core oligosaccharide O-antigen and lipid A as a kind of LPS.

In the present invention, the smooth LPS is secreted from bovine brucellosis-infected cattle and acts as an antigen to form an antibody against the bovine immune system, so that the antibody is detected from a bovine sample suspected of causing brucellosis , Can be used as a means to diagnose the onset of bovine brucellosis.

The fluorescence immunoassay kit provided in the present invention is not particularly limited as long as it comprises a condensate in which the co-marin dendrimer is bound with the protein A / G to immunologically detect the desired antibody, , More preferably a sandwich ELISA kit, and most preferably a sandwich FICT (fluorescent immunochromatographic test kit) kit in the form of a strip.

For example, the fluorescence immunoassay kit provided in the present invention can be prepared by binding a glass fiber, cotton or cellulose pad to a nitrocellulose membrane in the form of a strip and injecting a sample into which a blood sample can be injected (A mixture of a conjugate in which a protein A / G is conjugated to a comarine dendrimer and a conjugate in which a NUS protein is conjugated to a comarine dendrimer), a smooth mixture of the smooth LPS Immobilized test line and immunostrip or fluorescent immunochromatographic test kit (FICT) equipped with a control line to which an anti-NUS antibody capable of binding to the condensate to which the NUS protein is bound is immobilized on the co-marine dendrimer.

The term "NUS protein" of the present invention means a protein consisting of 495 amino acids and a molecular weight of 54.8 kDa expressed in Escherichia coli, also referred to as "NusA protein ". The NUS protein binds to an RNA polymerase and exhibits an activity of inducing or regulating transcription termination, exhibiting a solubility of about 95%, exhibiting a mass-expressed property, exhibiting reactivity with mammalian proteins There is a characteristic that it does not. A specific base sequence or amino acid sequence information of the gene encoding the NUS protein is known from NCBI (GenBank: EGT68887.1, etc.).

In the present invention, the NUS protein does not show reactivity with mammalian proteins. Therefore, the NUS protein can be used as a condensate for a fluorescent immunoassay kit for diagnosis of brucellosis provided by the present invention. For example, in the present invention, a condensate containing the NUS protein of SEQ ID NO: 1 was used.

The kit of the present invention can be used to detect an antibody produced by smooth LPS secreted in the brucellosis strain from a sample isolated from an animal suspected of having brucellosis, wherein the co-marin dendrimer is conjugated with a protein A / G In addition to the condensates, one or more other component compositions, solutions or devices suitable for the detection method may also be included. For example, a test tube or other suitable container, a reaction buffer, and the like.

According to one embodiment of the present invention, a fluorescent immunoassay kit for brucellosis diagnosis comprising a substrate on which smooth LPS of Brucella strain is bound and a condensate in which a protein A / G is conjugated to a comarine dendrimer is prepared.

When a sample isolated from a subject suffering from brucellosis is added to the kit, protein A / G of the conjugate binds to the constant region of the antibody contained in the sample due to the onset of brucellosis and binds to the antibody-condensate form Wherein the primary complex binds again to the antigen immobilized on the substrate to form a secondary complex in the form of an antigen-antibody-complex, the secondary complex is immobilized on a substrate, It was confirmed that the antibody produced due to the onset of brucellosis could be clearly detected using the kit thus prepared.

As another embodiment for achieving the above object, the present invention provides a method for diagnosing Brucellosis, comprising the step of adding to a fluorescent immunoassay kit for diagnosing brucellosis with a separated sample, ≪ / RTI >

Specifically, the method for diagnosing brucellosis in an animal other than human comprises the steps of: (a) obtaining a sample isolated from an animal other than a human suspected of having brucellosis; And (b) adding the obtained sample to a fluorescence immunoassay kit for diagnosing brucellosis, thereby detecting an antibody against a smooth LPS antigen derived from a brucellosis strain. At this time, the sample to be used is not particularly limited. Preferably, the sample such as nasal fluid, saliva, runny nose, sputum, blood, urine can be used alone or in combination.

The term "animal" of the present invention means a mammal, including a bovine, a dog, a sheep, a goat, a pig, etc., other than a person who has or is likely to develop brucellosis by infection of Brucella sp. Without limitation.

For example, a mixture of a coenzyme dendrimer of the present invention with a protein A / G-conjugated condensate and a comarine dendrimer with a NUS protein-conjugate condensate, a test substance immobilized on a test line and capable of detecting an antibody smooth LPS, fluorescent immunoassay kit for diagnosing brucellosis in which an antibody capable of detecting NUS protein is immobilized on a substrate, and a kit for detecting antibodies against smooth LPS of Brucella strain using the kit do.

That is, when the blood obtained from bovine blood suspected of having brucellosis is administered to the kit, the antibody contained therein reaches the condensate mixture in a lateral flow manner and binds to the protein A / G contained in the mixture, To form a conjugate having the form of a conjugate-antibody. When the conjugate moves to the test line, only the conjugate containing the anti-smooth LPS antibody among the conjugates having the form of the conjugate-antibody binds to and binds to the antigen bound to the test line. In addition, the condensate in which the NUS protein is bound to the co-marine dendrimer contained in the above-mentioned condensate mixture is transported to the tank by the side flow method by the introduction of the above plasma, and is then bound to the anti-NUS antibody bound to the tank line, . When the LED was irradiated to the kit in which the reaction was terminated, fluorescence was developed on the test line and the control line by the co-marin dendrimer, and the resultant was measured using a detector to determine whether an antibody against smooth LPS of the brucellosis strain was present Or not.

The fluorescence immunoassay kit for diagnosing brucellosis of the present invention comprises a substrate immobilized with a Smooth LPS antigen derived from a brucella strain and a condensate in which a protein A / G is conjugated to a comarine dendrimer. Even when a small amount of a sample is used, Can be effectively used for diagnosis of brucellosis.

BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a schematic diagram showing a process for synthesizing a precursor compound of a comarine skeleton from 2-hydroxy-4-nitrobenzoic acid. FIG.
FIG. 2 is a schematic diagram showing a process of synthesizing a linker having three azido groups. FIG.
FIG. 3 is a schematic view showing a process of preparing a desired comal dendrimer by linking a linker with a synthetic precursor compound of a comarene skeleton.
4A to 4C are graphs and tables showing the results of verifying the quantitative analysis ability of the fluorescent immunoassay kit for brucellosis diagnosis of the present invention using 6 Brucella disease positive serum dilutions, FIG. 4B is a graph showing the results obtained by applying the diluted product of one serum (serum ID 8888) to a fluorescent immunoassay kit for diagnosis of brucellosis, And the remaining five dilutions of the six sera were applied to a fluorescence immunoassay kit for the diagnosis of brucellosis and quantitatively analyzed.

Hereinafter, the present invention will be described in more detail with reference to examples. However, these examples are for illustrative purposes only, and the scope of the present invention is not limited to these examples.

Example  1: Preparation of antigens for diagnosis of brucellosis

The brucella strain ( B. abortus 1119-3) capable of inducing brucellosis was cultivated in a brucella potato infusion agar, and the strain cultured with 0.5% phenol-saline was recovered. The recovered strain was washed , Inactivated at 80 ° C for 1 hour, and smooth-LPS was extracted from the strain using a hot water / hot phenol method. Specifically, 170 mg of DW at 66 ° C and 190 ml of 90% phenol were added to 50 g of the above-mentioned homogenate, and the mixture was reacted for 20 minutes to extract LPS. The extract was centrifuged to obtain a phenol fraction. To the resulting phenol fraction was added 500 ml of methanol containing 1% of methanol saturated with sodium acetate, and the mixture was reacted to obtain a precipitate. The precipitate was suspended in distilled water and then centrifuged to obtain a supernatant. TCA (trichloroacetic acid) was added to the obtained supernatant to precipitate proteins, and then supernatants were obtained. The obtained supernatant was treated with trypsin (0.05%, w / v) to obtain a reaction product, and the obtained reaction product was dialyzed against distilled water and lyophilized to prepare smooth LPS. smooth LPS was used as an antigen for diagnosis of brucellosis.

Example  2: Comarine Dendrimer's  making

In order to synthesize a thioisocyanate (-NCS) group that can effectively bind to the amino group at the terminal of the lysine group, it is possible to introduce various substituents among the various skeletons effectively detectable in the LED, coumarin skeleton was selected to prepare a comain dendrimer having a thioisocyanate introduced into the skeleton.

First, a synthesis precursor compound of a comarine skeleton was synthesized from 2-hydroxy-4-nitrobenzoic acid through several steps (FIG. 1).

BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a schematic diagram showing a process for synthesizing a precursor compound of a comarine skeleton from 2-hydroxy-4-nitrobenzoic acid. FIG.

Next, in order to obtain another precursor required for the synthesis of the comarene skeleton, 2-aminothiophenol was condensed with ethyl cyanoacetate at 120 ° C without solvent to form three azido groups, (Fig. 2). The synthesized linker can bind three benzothiazolyl groups and is used as a core component of the fluorescent material.

FIG. 2 is a schematic diagram showing a process of synthesizing a linker having three azido groups. FIG.

Finally, the desired precursor coumarin 3-dendrimer was prepared by linking the synthesized precursor compound of the respective comerine skeleton with the linker (FIG. 3).

FIG. 3 is a schematic view showing a process of preparing a desired comal dendrimer by linking a linker with a synthetic precursor compound of a comarene skeleton.

The prepared co-marin dendrimer was dissolved in DMSO to prevent precipitation by mutual binding.

Example  3: Diagnosis of Brucellosis Condensate  Produce

Protein A / G was bound to the comal dendrimer prepared in Example 2 to prepare a brucella diagnostic condensate (test group condensate).

Specifically, 6% equivalent of a comain dendrimer was added to a solution of a protein A / G (1 mg / ml) dissolved in 0.1 M phosphate buffer, and the mixture was reacted under light shielding conditions and at room temperature for 2 hours with stirring. Then, BSA was added to the reaction solution so as to have a concentration of 1% (w / v), and the reaction was carried out under the same conditions for 2 hours. After completion of the reaction, the reaction product was dialyzed overnight to prepare a diagnostic blend of brucellosis.

In the same manner as described above, except that the NUS protein was used instead of the protein A / G for use as an internal control, a condensate in which the NUS protein was conjugated with a comarin dendrimer (a control condensate ).

Example  4: Diagnosis of Brucellosis Fluorescence Immunodiagnostic Kit  making

A fluorescence immunoassay kit for diagnosing brucellosis, comprising the condensate prepared in Example 3, was prepared.

Specifically, a sample injecting unit capable of injecting a sample by bonding a pad made of glass fiber, cotton or cellulose to one end of a strip-shaped nitrocellulose membrane is provided. A mixture of the test group condensate prepared in Example 3 and the control group condensate was added at a predetermined distance from the sample injecting portion and the test line was set at a predetermined interval from the mixture, The smooth LPS prepared in Example 1 was added at a concentration of 0.8 mg / ml and fixed.

A control line was set at a predetermined interval from the above-mentioned inspecting line, and an anti-Nus 5C4 MAb antibody (NUS 5C4 MAb) contained in the control group-containing conjugate was added to the control line and fixed at a concentration of 1 mg / ml.

As a result, in order to detect the antibody against the smooth LPS derived from the brucella strain contained in the sample, a fluorescent immunizing agent such as a sample pad, a condensate mixture, a test line and a control line are sequentially arranged on a strip-shaped nitrocellulose membrane A fluorescent immunochromatographic test (FICT) was made.

After adding the sample to the fluorescence immunoassay kit, a developing solution (0.1 M Tris, pH 8.5, 1% Tween 20, 500 mM NaCl and 0.1% NaN ₃ ) used for smooth detection was prepared.

Example  5: Diagnosis of Brucellosis Fluorescence Immunodiagnostic Kit  Performance evaluation

Example  5-1: Diagnosis of Brucellosis Fluorescence Immunodiagnostic Kit Quantitative analysis capability  Verification

In order to verify the quantitative analysis ability of the fluorescent immunoassay kit for brucellosis diagnosis prepared in Example 4, quantitative analysis was performed by applying six brucellosis-positive serum dilutions derived from bovine (FIGS. 4A to 4C) .

4A to 4C are graphs and tables showing the results of verifying the quantitative analysis ability of the fluorescent immunoassay kit for brucellosis diagnosis of the present invention using 6 Brucella disease positive serum dilutions, FIG. 4B is a graph showing the results obtained by applying the diluted product of one serum (serum ID 8888) to a fluorescent immunoassay kit for diagnosis of brucellosis, And the remaining five dilutions of the six sera were applied to a fluorescence immunoassay kit for the diagnosis of brucellosis and quantitatively analyzed.

As shown in FIGS. 4A to 4C, since the R ² value was 0.93 or more, it was confirmed that the quantitative test using the fluorescent immunoassay kit for brucellosis diagnosis of the present invention was possible.

Example  5-2: Diagnosis of Brucellosis Fluorescence immunoassay kit ELISA Of kit Analytical ability  compare

ELISA kits for diagnosis of brucellosis and the conventional brucellosis diagnosis using the dilution of one sample (serum ID 8888) in the samples used in Example 5-1 were analyzed And then compared them (Table 1). At this time, SD showed a standard deviation, and when the value measured by the I-ELISA kit was 40 or more, it was judged to be positive.

Brucellosis Diagnosis Efficacy Comparison Dilution factor The kit I-ELISA Kit result 1st 2nd Average SD PP (> 40) 8 times
16 times
32 times
64 times 1330
1275
1175
1140 1245
1188
1138
1100 1287.5
1231.5
1156.5
1120.0 42.5
43.5
18.5
20.0 75.62
66.05
46.61
31.84 positivity
positivity
positivity
voice

As shown in Table 1, it was confirmed that the fluorescence immunoassay kit for diagnosing brucellosis of the present invention exhibits equivalent or superior detection ability as compared with the I-ELISA kit.

Example  5-3: Diagnosis of Brucellosis Fluorescence Immunodiagnostic Kit  Sensitivity and specificity assessment

Sensitivity and specificity of the fluorescent immunoassay kit for the diagnosis of brucellosis were evaluated using 102 positive brucela sera and 59 negative sera obtained from cattle. At this time, positive and negative serum samples were previously identified by RBT, Tube test, FPA and C-ELISA.

Sensitivity and specificity of fluorescence immunoassay kit for diagnosis of brucellosis Judgment result Positive serum (n = 102) Negative serum (n = 59) Kappa Value positivity
voice 101
One 0
59 0.99 Diagnostic accuracy 99% 100%

As shown in Table 2, the fluorescence immunoassay kit for diagnosing brucellosis of the present invention showed high sensitivity and specificity.

Example  5-4: Positive  or Weakly positive  Diagnosis of brucellosis in samples Neon Performance evaluation of immunoassay kit

In order to confirm whether the fluorescent immunoassay kit for diagnosing brucellosis of the present invention can be used for positive or weakly positive sera of the brucella disease, three positive or weakly positive sera derived from bovine, (Table 3). At this time, TUBE, I-ELISA kit and C-ELISA kit were used as comparative groups.

Of fluorescent immunoassay kit for the diagnosis of brucellosis of positive or weakly positive samples serum TUBE (> 50) I-ELISA kit (> 80) C-ELISA kit (> 40) The kit cattle4
cattle5
cattle6 <50
100 ±
100 ± 105
115
120 40
54
41 +
+
-

As shown in Table 3 above, the serum showing positive or weak positive using the tube agglutination reaction method, I-ELISA kit and C-ELISA kit currently used in domestic and foreign countries is used for the fluorescent immunoassay kit for diagnosis of brucellosis of the present invention When applied, they were able to distinguish between normal positive blood donations.

Example  5-5: Performance evaluation of fluorescence immunoassay kit for diagnosis of brucellosis of non-specific cross-reacting samples

In order to confirm whether or not the fluorescent immunoassay kit for diagnosis of brucellosis of the present invention can be used for non-specific cross-reacting sera, the bovine artificial infection with Y. enterocolitica O9, E. coli O157: H7 or Salmonella typhi bacteria The blood serum was used to evaluate the performance of the fluorescent immunoassay kit for the diagnosis of brucellosis (Table 4).

Performance of fluorescence immunoassay kit for the diagnosis of brucellosis in non-specific cross-reacting samples Infectious strain individual
number Tube coagulant antibody (elapsed days, weeks) The kit One 2 3 4 5 Y. enterocolitica O9 3413
3709
9810
7785 +200
+100
+200
+200 ± 200
± 50
± 200
± 200 ± 100
+25
± 100
+25 +50
+50
+25
+25 +50
+25
+50
+50 -
-
-
- E. coli O157: H7 6164 +100 ± 100 +25 +25 +50 - Salmonella typhi 6342 +100 ± 25 - - - -

As shown in Table 4, the fluorescence immunoassay kit for diagnosing brucellosis of the present invention showed no specificity due to nonspecific reaction, and thus its specificity was confirmed even for sera from 25 to 200 times of Tube agglutination antibody.

Example  5-6: For other animals Brucellosis  For diagnostic purposes Fluorescence Immunodiagnostic Kit  Performance evaluation

In order to confirm whether or not the fluorescent immunoassay kit for diagnosing brucellosis of the present invention can be used for brucellosis caused in animals other than cows, six positive sera derived from chlorine were used to prepare a fluorescent immunoassay kit for brucellosis diagnosis (Table 5).

Performance of a fluorescent immunoassay kit for the diagnosis of brucellosis of chlorine serum serum TUBE (> 50) I-ELISA kit (> 80) C-ELISA kit (> 40) The kit goat 1
goat 2
goat 4
goat 5
goat 6
goat 7 <50
200
50
200
<50
<50 104
104
104
100
98
91 74
95
87
95
62
61 +
+
+
+
+
-

As shown in Table 5, it was found that the present invention can be diagnosed using the fluorescent immunoassay kit for diagnosing brucellosis of the present invention in the diagnosis of brucellosis caused in other animals such as goat, not cow.

<110> GenBody Inc.          REPUBLIC OF KOREA (Ministry of Agriculture, Food and Rural Affairs, Animal and Plant Quarantine Agency) <120> Kit for fluorescence-linked immunochromatographic assay to          diagnose brucellosis <130> KPA141241-KR <160> 1 <170> Kopatentin 2.0 <210> 1 <211> 495 <212> PRT <213> Artificial Sequence <220> <223> recombinant NUS <400> 1 Met Asn Lys Glu Ile Leu Ala Val Val Glu Ala Val Ser Asn Glu Lys   1 5 10 15 Ala Leu Pro Arg Glu Lys Ile Phe Glu Ala Leu Glu Ser Ala Leu Ala              20 25 30 Thr Ala Thr Lys Lys Lys Tyr Glu Gln Glu Ile Asp Val Arg Val Gln          35 40 45 Ile Asp Arg Lys Ser Gly Asp Phe Asp Thr Phe Arg Arg Trp Leu Val      50 55 60 Val Asp Glu Val Thr Gln Pro Thr Lys Glu Ile Thr Leu Glu Ala Ala  65 70 75 80 Arg Tyr Glu Asp Glu Ser Leu Asn Leu Gly Asp Tyr Val Glu Asp Gln                  85 90 95 Ile Glu Ser Val Thr Phe Asp Arg Ile Thr Thr Gln Thr Ala Lys Gln             100 105 110 Val Ile Val Gln Lys Val Arg Glu Ala Glu Arg Ala Met Val Val Asp         115 120 125 Gln Phe Arg Glu His Glu Gly Glu Ile Ile Thr Gly Val Val Lys Lys     130 135 140 Val Asn Arg Asp Asn Ile Ser Leu Asp Leu Gly Asn Asn Ala Glu Ala 145 150 155 160 Val Ile Leu Arg Glu Asp Met Leu Pro Arg Glu Asn Phe Arg Pro Gly                 165 170 175 Asp Arg Val Gly Val Leu Tyr Ser Val Arg Pro Glu Ala Arg Gly             180 185 190 Val Gln Leu Phe Val Thr Arg Ser Lys Pro Glu Met Leu Ile Glu Leu         195 200 205 Phe Arg Ile Glu Val Pro Glu Ile Gly Glu Glu Val Ile Glu Ile Lys     210 215 220 Ala Ala Ala Arg Asp Pro Gly Ser Arg Ala Lys Ile Ala Val Lys Thr 225 230 235 240 Asn Asp Lys Arg Ile Asp Pro Val Gly Ala Cys Val Gly Met Arg Gly                 245 250 255 Ala Arg Val Gln Ala Val Ser Thr Glu Leu Gly Gly Glu Arg Ile Asp             260 265 270 Ile Val Leu Trp Asp Asp Asn Pro Ala Gln Phe Val Ile Asn Ala Met         275 280 285 Ala Pro Ala Asp Val Ala Ser Ile Val Val Asp Glu Asp Lys His Thr     290 295 300 Met Asp Ile Ala Val Glu Ala Gly Asn Leu Ala Gln Ala Ile Gly Arg 305 310 315 320 Asn Gly Gln Asn Val Arg Leu Ala Ser Gln Leu Ser Gly Trp Glu Leu                 325 330 335 Asn Val Met Thr Val Asp Asp Leu Gln Ala Lys His Gln Ala Glu Ala             340 345 350 His Ala Ala Ile Asp Thr Phe Thr Lys Tyr Leu Asp Ile Asp Glu Asp         355 360 365 Phe Ala Thr Val Leu Val Glu Glu Gly Phe Ser Thr Leu Glu Glu Leu     370 375 380 Ala Tyr Val Met Lys Glu Leu Leu Glu Ile Glu Gly Leu Asp Glu 385 390 395 400 Pro Thr Val Glu Ala Leu Arg Glu Arg Ala Lys Asn Ala Leu Ala Thr                 405 410 415 Ile Ala Gln Ala Gln Glu Glu Ser Leu Gly Asp Asn Lys Pro Cys Asp             420 425 430 Asp Leu Leu Asn Leu Glu Gly Val Asp Arg Asp Leu Ala Phe Lys Leu         435 440 445 Ala Ala Arg Gly Val Cys Ser Leu Glu Asp Leu Ala Glu Gln Gly Ile     450 455 460 Asp Asp Leu Ala Asp Ile Glu Gly Leu Thr Asp Glu Lys Ala Gly Ala 465 470 475 480 Leu Ile Met Ala Ala Arg Asn Ile Cys Trp Phe Gly Asp Glu Ala                 485 490 495

Claims (12)

A substrate on which smooth LPS (smooth lipopolysaccharide) antigen derived from Brucella strain is immobilized, a condensate in which a protein A / G is conjugated to a comarine dendrimer, and a condensate in which a NUS protein is conjugated to a comarine dendrimer, Immunoassay kit.
The method according to claim 1,
A kit for detecting an antibody against a Smooth LPS antigen in an animal in which brucellosis is caused to diagnose the onset of brucellosis.
The method according to claim 1,
Wherein the kit is a sandwich FICT (fluorescent immunochromatographic test) kit in the form of a strip.
The method of claim 3,
Wherein the FICT kit is in the form of a sample injection unit, a condensate mixture, an inspecting line and a control line provided in a strip-shaped nitrocellulose membrane.
5. The method of claim 4,
Wherein the sample injecting portion comprises a pad made of glass fiber, cotton or cellulose.
delete The method according to claim 1,
Wherein the NUS protein has the amino acid sequence of SEQ ID NO: 1.
5. The method of claim 4,
Wherein the test line is a form in which Smooth LPS is fixed to the nitrocellulose membrane.
5. The method of claim 4,
Wherein the control line is a form in which the anti-NUS antibody is immobilized on the nitrocellulose membrane.
(a) obtaining a sample isolated from an animal other than a human suspected of having an onset of brucellosis; And
(b) applying the obtained sample to the kit of any one of claims 1 to 5 and 7 to 9 to detect an antibody against a smooth LPS antigen derived from a brucellosis strain. A method for diagnosing brucellosis in an animal,
11. The method of claim 10,
Wherein said animal is a bovine, a dog, a sheep, a goat or a pig that can develop brucellosis by infection of Brucella sp.
11. The method of claim 10,
Wherein the sample is a test selected from the group consisting of nasal fluid, saliva, runny nose, sputum, blood, urine, and combinations thereof.

Images